🔎 Trials Near Me

홈 › 비호지킨 림프종 › 노스캐롤라이나

노스캐롤라이나의 비호지킨 림프종 임상 시험

비호지킨 림프종 관련 연구 24개가 노스캐롤라이나 내 여러 지역에서 참여자를 모집하고 있습니다.

노스캐롤라이나의 도시

공식 연구 텍스트(영어)

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

  • GC2202 Study Site 109, Greenville
  • GC2202 Decentralized Study Site 114, Morrisville
  • GC2202 Study Site 117, Wilson
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT05645107

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • Lineberger Comprehensive Cancer Center, Chapel Hill
  • Atrium Health's Levine Cancer Institute, Charlotte
피험자 모집 중2상
12세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT02693535

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

  • Research Site, Charlotte
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 11. 업데이트됨 · NCT06526793

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • Atrium Health Wake Forest Baptist, Winston-Salem
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT05826535

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
피험자 모집 중1/2상
13세 ~ 90세 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT06533579

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

  • Duke University Medical Center - Division of Hematologic Malignancies, Durham
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 8. 5. 업데이트됨 · NCT06116110

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Duke Cancer Institute, Durham
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 4. 업데이트됨 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • Duke University Medical Center - Division of Hematologic Malignancies, Durham
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 7. 13. 업데이트됨 · NCT04792489

Pre-malignant States to Hematologic Malignancies in Firefighters

  • Levine Cancer Institute, Charlotte
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 49세 · 모든 성별 · 2026. 7. 13. 업데이트됨 · NCT06870760

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • University of North Carolina at Chapel Hill, Chapel Hill
  • Levine Children's Hospital, Charlotte
  • Duke University Medical Center, Durham
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT01351545

Registry of Older Patients With Cancer

  • Seby B. Jones Cancer Center, Boone
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
  • East Carolina University, Greenville
  • 외 4개
피험자 모집 중관찰 연구
65세 이상 · 모든 성별 · 2026. 6. 29. 업데이트됨 · NCT01137825

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

  • University of North Carolina, Chapel Hill
피험자 모집 중1상
13세 이상 · 모든 성별 · 2026. 5. 5. 업데이트됨 · NCT04771572

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • Duke University Medical Center, Duke Cancer Center, Durham
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 4. 16. 업데이트됨 · NCT03328078

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

  • Wake Forest Baptist Health, Winston-Salem
피험자 모집 중관찰 연구
18세 ~ 120세 · 모든 성별 · 2026. 4. 13. 업데이트됨 · NCT01890486

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Atrium Health Stanly/LCI-Albemarle, Albemarle
  • Cone Health MedCenter Asheboro, Asheboro
  • Cone Health Cancer Center at Alamance Regional, Burlington
  • 외 21개
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 3. 17. 업데이트됨 · NCT06418204

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

  • Duke University Medical Center, Durham
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 3. 2. 업데이트됨 · NCT06876649

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

  • Duke University Medical Center, Durham
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 3. 2. 업데이트됨 · NCT06876662

Study of SGR-1505 in Mature B-Cell Neoplasms

  • Duke University, Durham
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 2. 13. 업데이트됨 · NCT05544019

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

  • Carolina BioOncology, Huntersville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 2. 4. 업데이트됨 · NCT05892718

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

  • Duke University, Durham
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 12. 10. 업데이트됨 · NCT05602363

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Chapel Hill
  • Massive Bio SYNERGY-AI site, Winston-Salem
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 10. 28. 업데이트됨 · NCT03452774

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
피험자 모집 중관찰 연구
18세 ~ 120세 · 모든 성별 · 2025. 10. 27. 업데이트됨 · NCT01137643

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  • University of North Carolina, Chapel Hill
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 10. 2. 업데이트됨 · NCT05780034

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

  • Atrium Health Wake Forest Baptist, Winston-Salem
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 6. 3. 업데이트됨 · NCT06119685

ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.